BAIYUNSHAN PH (00874.HK) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Dec22

BC Pharmaceutical Phase II Fund Participates in Establishing Guang Yao Guang Kai and Guang Yao Liwan Funds

11:58

Dec15

JPMorgan Cuts Stake in China Pharmaceutical Giant Baiyunshan

11:17

Dec6

Changsha Zhongyi Pharmaceutical's An Gong Niu Huang Pill Receives Drug Registration Certificate in Vietnam

01:10

Dec5

JPMorgan Raises Stake in Guangzhou Baiyunshan to 9.02%

11:05

Dec1

Guangzhou Pharmaceutical Plans to Launch Accounts Receivable Securitization Business

10:47

Guang 白云山 Holds Q3 2025 Earnings Briefing

03:36

Schedules & Filings

Schedules

Filings

Oct28

Earning Release(CST)

FY2025 Q3 Earning Release (HKD) Revenue 21.61 B, Net Income 867.88 M, EPS 0.5335

Sep26

Distribution Plan(CST)

Cash dividend 0.4399 HKD

Sep1

Distribution Plan(CST)

Cash dividend 0.4399 HKD

View More

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change

View More